215 related articles for article (PubMed ID: 24853577)
1. O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus.
Jergas B; Schulte K; Bindila L; Lutz B; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jul; 387(7):621-8. PubMed ID: 24853577
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta.
Schultheiss T; Flau K; Kathmann M; Göthert M; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2005 Aug; 372(2):139-46. PubMed ID: 16195872
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor.
Schulte K; Steingrüber N; Jergas B; Redmer A; Kurz CM; Buchalla R; Lutz B; Zimmer A; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):385-96. PubMed ID: 22215206
[TBL] [Abstract][Full Text] [Related]
4. Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation.
Makwana R; Molleman A; Parsons ME
Br J Pharmacol; 2010 Jun; 160(3):615-26. PubMed ID: 20590566
[TBL] [Abstract][Full Text] [Related]
5. A pharmacological paradox: may a neutral antagonist shift an agonist concentration-response curve to the left?
Feuerstein TJ
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jul; 387(7):601-3. PubMed ID: 24866501
[TBL] [Abstract][Full Text] [Related]
6. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus.
Béquet F; Uzabiaga F; Desbazeille M; Ludwiczak P; Maftouh M; Picard C; Scatton B; Le Fur G
Eur J Neurosci; 2007 Dec; 26(12):3458-64. PubMed ID: 18052990
[TBL] [Abstract][Full Text] [Related]
7. Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex.
Steffens M; Szabo B; Klar M; Rominger A; Zentner J; Feuerstein TJ
Neuroscience; 2003; 120(2):455-65. PubMed ID: 12890515
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain.
Kathmann M; Bauer U; Schlicker E; Göthert M
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):466-70. PubMed ID: 10431757
[TBL] [Abstract][Full Text] [Related]
9. Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors.
Silva GB; Atchison DK; Juncos LI; García NH
Am J Physiol Renal Physiol; 2013 Feb; 304(4):F376-81. PubMed ID: 23220721
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity.
Hampson RE; Miller F; Palchik G; Deadwyler SA
Neuropharmacology; 2011 May; 60(6):944-52. PubMed ID: 21288475
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid- and mGluR5-dependent short-term synaptic depression in an isolated neuron/bouton preparation from the hippocampal CA1 region.
Sheinin A; Talani G; Davis MI; Lovinger DM
J Neurophysiol; 2008 Aug; 100(2):1041-52. PubMed ID: 18497350
[TBL] [Abstract][Full Text] [Related]
12. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.
Rubio M; Fernández-Ruiz J; de Miguel R; Maestro B; Michael Walker J; Ramos JA
Neuropharmacology; 2008 May; 54(6):976-88. PubMed ID: 18371990
[TBL] [Abstract][Full Text] [Related]
13. Increased Contextual Fear Conditioning in iNOS Knockout Mice: Additional Evidence for the Involvement of Nitric Oxide in Stress-Related Disorders and Contribution of the Endocannabinoid System.
Lisboa SF; Gomes FV; Silva AL; Uliana DL; Camargo LH; Guimarães FS; Cunha FQ; Joca SR; Resstel LB
Int J Neuropsychopharmacol; 2015 Jan; 18(8):. PubMed ID: 25618404
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid receptor agonists modulate calcium channels in rat retinal Müller cells.
Yang W; Li Q; Wang SY; Gao F; Qian WJ; Li F; Ji M; Sun XH; Miao Y; Wang Z
Neuroscience; 2016 Jan; 313():213-24. PubMed ID: 26621126
[TBL] [Abstract][Full Text] [Related]
15. Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses.
Kim J; Alger BE
Nat Neurosci; 2010 May; 13(5):592-600. PubMed ID: 20348918
[TBL] [Abstract][Full Text] [Related]
16. Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release.
Schlicker E; Redmer A; Werner A; Kathmann M
Br J Pharmacol; 2003 Sep; 140(2):323-8. PubMed ID: 12970076
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Aug; 56(2):132-9. PubMed ID: 17574859
[TBL] [Abstract][Full Text] [Related]
18. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.
Lauckner JE; Hille B; Mackie K
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19144-9. PubMed ID: 16365309
[TBL] [Abstract][Full Text] [Related]
19. Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state.
Rea K; Ford GK; Olango WM; Harhen B; Roche M; Finn DP
Eur J Neurosci; 2014 Feb; 39(3):435-43. PubMed ID: 24494683
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
